TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25479899

Group type: EXPERIMENTAL
Intervention: Patients with MR or PE
Number of subjects: 110

Group type: COMPARATOR
Intervention: Patients without MR or PE
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Patients with abnormal coronary arteries and MR or PE
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Patients with MR or PE at 3-week follow-up
Number of subjects: 110

Group type: COMPARATOR
Intervention: Patients without MR or PE at 3-week follow-up
Number of subjects: 110
Study: 22414053

Group type: EXPERIMENTAL
Intervention: Pancreatic duct (PD) stenting following endoscopic sphincterotomy (EST)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST) alone
Number of subjects: 141
Study: 20233598

Group type: EXPERIMENTAL
Intervention: Conventional Cigarette (CC)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Electrically Heated Smoking System (EHCSS)
Number of subjects: 57

Group type: COMPARATOR
Intervention: No Smoking (NS)
Number of subjects: 57
Study: 18803446

Group type: EXPERIMENTAL
Intervention: Memantine and donepezil (individually or in combination)
Number of subjects: 9
Study: 15950835

Group type: EXPERIMENTAL
Intervention: Patient education programme (un souffle nouveau)
Number of subjects: 238
Study: 12182748

Group type: EXPERIMENTAL
Intervention: ABT-229 5 mg b.d.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ABT-229 10 mg b.d.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ABT-229 2.5 mg b.d.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: ABT-229 (all doses)
Number of subjects: 21
Study: 10350664

Group type: EXPERIMENTAL
Intervention: Cerivastatin (0.05 to 0.3 mg/day)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Simvastatin (5 to 40 mg/day)
Number of subjects: 387
Study: 7703043

Group type: EXPERIMENTAL
Intervention: Doxorubicin (270 to 300 mg/m2 cumulative dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vincristine and dactinomycin (without doxorubicin)
Number of subjects: 12
Study: 1838289

Group type: EXPERIMENTAL
Intervention: Intravenous magnesium
Number of subjects: 1301

Group type: COMPARATOR
Intervention: Control (similar treatment without magnesium)
Number of subjects: 1301
Study: 6121518

Group type: EXPERIMENTAL
Intervention: Nuelin Depot
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TheoDur
Number of subjects: 20
Study: 31268267

Group type: EXPERIMENTAL
Intervention: Neurostimulator guided rectus sheath block (NS guided RSB)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ultrasound guided rectus sheath block (US guided RSB)
Number of subjects: 116
Study: 30382824

Group type: EXPERIMENTAL
Intervention: RTX plus MMF (1000-1200 mg/m2/day, maximum 2 g/day, twice daily for 17 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RTX plus placebo
Number of subjects: 0
Study: 27583404

Group type: EXPERIMENTAL
Intervention: Intensive Treatment (IT)
Number of subjects: 3055

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 3055
Study: 24355663

Group type: EXPERIMENTAL
Intervention: Supervised exercise training (SET) for 3 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (PAD-only)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: T2D+PAD group
Number of subjects: 27
Study: 21425387

Group type: EXPERIMENTAL
Intervention: Question Prompt Sheet (QPS) and Hospital Introduction Sheet (HIS)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Hospital Introduction Sheet (HIS) only
Number of subjects: 63
Study: 20565725

Group type: EXPERIMENTAL
Intervention: 0.6 mg oral salmon calcitonin (sCT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.8 mg oral salmon calcitonin (sCT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 17384931

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous haemofiltration (CVVH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Extended daily dialysis with filtration (EDDf)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (CVVH)
Number of subjects: 16
Study: 16123553

Group type: EXPERIMENTAL
Intervention: Superior hinge flap technique
Number of subjects: 106

Group type: COMPARATOR
Intervention: Nasal hinge flap technique
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Subjective evaluation of dry eye symptoms (OSDI questionnaire) at 1, 3, and 6 months
Number of subjects: 106
Study: 14607735

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: TACE+MLT (melatonin 20 mg/d orally, 7 days before TACE)
Number of subjects: 100
Study: 10563127

Group type: EXPERIMENTAL
Intervention: Partially inflated laryngeal mask (75% volume)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Deflated laryngeal mask (uninflated)
Number of subjects: 60
Study: 7485886

Group type: EXPERIMENTAL
Intervention: 3 ml isobaric 0.5% bupivacaine intrathecally without aspirating cerebrospinal fluid
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 ml isobaric 0.5% bupivacaine mixed with 1 ml cerebrospinal fluid (total 4 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3 ml isobaric 0.5% bupivacaine mixed with 2 ml cerebrospinal fluid (total 5 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 60
Study: 2258790

Group type: EXPERIMENTAL
Intervention: Combination of 160 mg verapamil with 25 mg hydrochlorothiazide and 50 mg triameterene
Number of subjects: 216

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 7218018

Group type: EXPERIMENTAL
Intervention: 30 cc of milk of magnesia plus 5 cc of cascara
Number of subjects: 50

Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 50
Study: 31492516

Group type: EXPERIMENTAL
Intervention: Adaptive CRT (aCRT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Echo-guided BiV pacing
Number of subjects: 39
Study: 29425477

Group type: EXPERIMENTAL
Intervention: Sumac capsules (500 mg/twice daily)
Number of subjects: 30
Study: 27380614

Group type: EXPERIMENTAL
Intervention: Endoscopic marking with purified carbon particles (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No marking (n=20)
Number of subjects: 40
Study: 24568125

Group type: EXPERIMENTAL
Intervention: HEIA-intervention (school-based multiple-behaviour study)
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Parental regulation (reported by parents and adolescents)
Number of subjects: 1418

Group type: COMPARATOR
Intervention: Parental regulation (reported by parents)
Number of subjects: 1418
Study: 22085227

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy plus tadalafil 5 mg once daily for 4 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Extracorporeal shock wave therapy alone for 4 weeks
Number of subjects: 100
Study: 20846487

Group type: EXPERIMENTAL
Intervention: Sodium iodide associated to salicylic acid (SISA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 40
Study: 17593233

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with a short‐acting insulin analogue, 2 IU/h, for 8 h during three consecutive nights (period A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) with a short‐acting insulin analogue, 2 IU/h, for 8 h during three consecutive nights (period B and C)
Number of subjects: 10
Study: 15886752

Group type: COMPARATOR
Intervention: Estradiol in Group A (AD)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Progesterone in Group A (AD)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Testosterone in Group A (AD)
Number of subjects: 88

Group type: COMPARATOR
Intervention: FSH in Group A (AD)
Number of subjects: 88

Group type: COMPARATOR
Intervention: LH in Group A (AD)
Number of subjects: 88
Study: 12519875

Group type: EXPERIMENTAL
Intervention: Discontinuation of GH treatment (3 IU/m2 x d)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Discontinuation of GH treatment (6 IU/m2 x d)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Discontinuation of GH treatment (both dosage groups)
Number of subjects: 47
Study: 11191785

Group type: EXPERIMENTAL
Intervention: Low level (procedure-based) training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High level (system-based) training
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: First testing session
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Second testing session (8 months later)
Number of subjects: 25
Study: 9169959

Group type: EXPERIMENTAL
Intervention: Nefazodone 200 mg daily for 1 week, followed by 400 mg daily for 7 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Fluoxetine 20 mg daily
Number of subjects: 43
Study: 1328700

Group type: EXPERIMENTAL
Intervention: PCR
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Viral culture
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tzanck smear
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 2866047

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30184183

Group type: EXPERIMENTAL
Intervention: PCV10
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 262

Group type: COMPARATOR
Intervention: PCV10 and PCV13
Number of subjects: 262
Study: 29769133

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 0
Study: 27428209

Group type: EXPERIMENTAL
Intervention: PEG‐Asc plus simethicone
Number of subjects: 260

Group type: COMPARATOR
Intervention: PEG‐Asc
Number of subjects: 260
Study: 25948426

Group type: EXPERIMENTAL
Intervention: Shiatsu technique (30 seconds on three points by an experienced midwife)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Routine procedure (control group)
Number of subjects: 288
Study: 21778014

Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Blood clot (control group)
Number of subjects: 15
Study: 20710020

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg kg(‐1) bolus dose followed by a 5‐20‐40‐120 min, 10‐8‐6‐5 mg kg(‐1) h(‐1) infusion.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Allometric model using total body weight (TBW) as the size descriptor.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pooled analysis from 51 patients including obese and non-obese data.
Number of subjects: 19
Study: 18096680

Group type: EXPERIMENTAL
Intervention: Cerebral Ischaemia and Atrial Fibrillation (CIAF)
Number of subjects: 2659

Group type: COMPARATOR
Intervention: Cerebral Ischaemia of Arterial Origin (CIAO)
Number of subjects: 2659
Study: 16171718

Group type: EXPERIMENTAL
Intervention: Estrogen (n = 7)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Estrogen plus progesterone (n = 8)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No hormone replacement (n = 9)
Number of subjects: 24
Study: 12767571

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 150 mg administered orally on days 5 through 9 of the CC-induced cycle
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spontaneous cycles
Number of subjects: 20
Study: 10489026

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 22 microg weekly
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 44 microg weekly
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10180841

Group type: EXPERIMENTAL
Intervention: 38-item module on BPH-specific health status first, followed by a 30-item module on overall health status
Number of subjects: 392

Group type: COMPARATOR
Intervention: 30-item module on overall health status first, followed by a 38-item module on BPH-specific health status
Number of subjects: 392
Study: 1881695

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: Amoxicillin + Metronidazole
Number of subjects: 30
Study: 6378355

Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (PGT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (no prophylactic granulocyte transfusions)
Number of subjects: 35
Study: 31488462

Group type: EXPERIMENTAL
Intervention: Healthcare Transformation Plan (HTP) implemented in Iran in 2016
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pre-reform group (2012)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Post-reform group (2016)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Post-HTP (2016)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pre-HTP (2012)
Number of subjects: 200
Study: 29959105

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for increasing physical activity (n = 140)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Attention and social contact control (n = 140)
Number of subjects: 280
Study: 26999243

Group type: EXPERIMENTAL
Intervention: sLPD (0.6 g/kg/d with 0.09 g/kg/d keto acids)
Number of subjects: 108

Group type: COMPARATOR
Intervention: NPD (1.0 g/kg/d)
Number of subjects: 108
Study: 24534120

Group type: EXPERIMENTAL
Intervention: CT-guided fiducial seed placement alone
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: CT-guided fiducial seed placement with concurrent biopsy
Number of subjects: 285

Group type: COMPARATOR
Intervention: Core biopsy alone
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: All groups (fiducial only, biopsy only, combined)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Fiducial only
Number of subjects: 285

Group type: COMPARATOR
Intervention: Biopsy only
Number of subjects: 285
Study: 22186223

Group type: EXPERIMENTAL
Intervention: Combined treatment with potassium bromide (1 g, tid) and methimazole (10 mg, tid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methimazole only (10 mg, tid) with starch placebo (1 g, tid)
Number of subjects: 60
Study: 20397591

Group type: EXPERIMENTAL
Intervention: Suspicion as a source feature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suspicion as a receptor's personal disposition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dispositional suspicion
Number of subjects: 0
Study: 22766026

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 15695749

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164

Group type: COMPARATOR
Intervention: Healthy controls and epilepsy patient controls
Number of subjects: 164
Study: 12721780

Group type: EXPERIMENTAL
Intervention: Alcohol (0.25, 0.50, 0.75 g/kg based on total body water)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No alcohol administration
Number of subjects: 32
Study: 10226770

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) administered orally to 24 patients
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group of 21 patients without pentoxifylline administration
Number of subjects: 45
Study: 8679274

Group type: EXPERIMENTAL
Intervention: Vitamin supplementation with beta-carotene (30 mg/d) and alpha-tocopherol (400 IU/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 1859950

Group type: EXPERIMENTAL
Intervention: Maternal alcohol consumption before and after pregnancy
Number of subjects: 846

Group type: COMPARATOR
Intervention: No alcohol consumption
Number of subjects: 846
Study: 6413133

Group type: EXPERIMENTAL
Intervention: Branched chain amino acid (BcAA) enriched parenteral nutrition at doses of 0.16, 0.3, 0.5, and 0.7 g/kg . day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Branched chain amino acid (BcAA) enriched parenteral nutrition
Number of subjects: 32

Group type: COMPARATOR
Intervention: Balanced nutritional support with 30 glucose cal/kg . day and 7 cal/kg . day of iv fat
Number of subjects: 32
Study: 29248827

Group type: EXPERIMENTAL
Intervention: Dietary counseling
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no dietary counseling)
Number of subjects: 200
Study: 23907163

Group type: EXPERIMENTAL
Intervention: Curriculum progression adjustments based on formative assessments (e.g. repeat lessons, skip lessons) every 4 weeks.
Number of subjects: 136

Group type: COMPARATOR
Intervention: Standard implementation without adjustments (control group, n = 101).
Number of subjects: 136
Study: 23110783

Group type: EXPERIMENTAL
Intervention: Repeated exposure to artichoke (10 exposures)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flavour-flavour learning (10 exposures to artichoke)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Flavour-nutrient learning (10 exposures to artichoke)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control vegetable (carrot)
Number of subjects: 72
Study: 20600032

Group type: EXPERIMENTAL
Intervention: Budesonide (3 mg, three times daily or twice daily) + Azathioprine (1-2 mg/kg/d)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Prednisone (40 mg/d, tapered to 10 mg/d) + Azathioprine (1-2 mg/kg/d)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Budesonide (after 6 months of prednisone) + Azathioprine (1-2 mg/kg/d)
Number of subjects: 203
Study: 18251597

Group type: EXPERIMENTAL
Intervention: Eruption guidance appliance
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study: 17109751

Group type: EXPERIMENTAL
Intervention: Hybrid-pump procedure
Number of subjects: 109

Group type: COMPARATOR
Intervention: On-pump coronary bypass
Number of subjects: 109
Study: 12626350

Group type: EXPERIMENTAL
Intervention: Oral arginine therapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Arginase activity measurement
Number of subjects: 10
Study: 10741622

Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with 200 mL grapefruit juice (G0)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with 200 mL grapefruit juice (G14)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 10 mg oral nisoldipine with water (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with water (G38)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with water (G72)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5 mg oral nisoldipine with water (G96)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: G0, G14, G38
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: G0
Number of subjects: 8
Study: 9015467

Group type: EXPERIMENTAL
Intervention: Ciprofibrate 100 mg once daily
Number of subjects: 174

Group type: COMPARATOR
Intervention: Bezafibrate 400 mg once daily
Number of subjects: 174
Study: 1999932

Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard posterolateral thoracotomy
Number of subjects: 50
Study: 6352622

Group type: EXPERIMENTAL
Intervention: ceftazidime 2 g bd
Number of subjects: 50

Group type: COMPARATOR
Intervention: cefamandole 2 g tds and tobramycin 80 mg bd
Number of subjects: 50
Study: 30549498

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study: 26164019

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.025 μg) once daily for 14 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo capsule once daily for 14 days
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Baseline vitamin D level association
Number of subjects: 28
Study: 24931840

Group type: EXPERIMENTAL
Intervention: Cross-match-compatible platelets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Randomly selected and incompatible platelets
Number of subjects: 40
Study: 22735900

Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 54
Study: 20851460

Group type: EXPERIMENTAL
Intervention: 0.5% PRO2000 gel
Number of subjects: 9385

Group type: EXPERIMENTAL
Intervention: 2% PRO2000 gel
Number of subjects: 9385

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 9385
Study: 18270569

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulfadoxine-pyrimethamine (AQ+SP)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Chloroquine + Sulfadoxine-pyrimethamine (CQ+SP)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Artesunate + Sulfadoxine-pyrimethamine (ART+SP)
Number of subjects: 455
Study: 15708255

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) radiotherapy, 2 Gy daily up to 60 Gy in 6 weeks
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) radiotherapy, biphasic concomitant boost schedule delivering 64 Gy in 5 weeks
Number of subjects: 226

Group type: COMPARATOR
Intervention: Conventional fractionation (CF) radiotherapy
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF) radiotherapy
Number of subjects: 226
Study: 11870157

Group type: EXPERIMENTAL
Intervention: High-dose radiation therapy (64.8 Gy)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard-dose radiation therapy (50.4 Gy)
Number of subjects: 236
Study: 10203111

Group type: EXPERIMENTAL
Intervention: Annual preventive in-home comprehensive geriatric assessment (CGA) with quarterly home visits by gerontologic nurse practitioners for 3 years
Number of subjects: 294
Study: 7572737

Group type: EXPERIMENTAL
Intervention: Yogurt preload (low-fat, low-energy, 962 kJ)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Yogurt preload (high-fat, high-energy, 2134 kJ)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Yogurt preload (high-carbohydrate, high-energy, 2134 kJ)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No yogurt (baseline condition)
Number of subjects: 32
Study: 2331093

Group type: EXPERIMENTAL
Intervention: Lighted stylet
Number of subjects: 80

Group type: COMPARATOR
Intervention: Blind nasotracheal intubation
Number of subjects: 80
Study: 299220

Group type: EXPERIMENTAL
Intervention: T‐antigen immunotherapy combined with cytostatic therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cytostatics only
Number of subjects: 40